CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $56.26, indicating a -2.46% shift from the previous…
48,400€
-1,83%
Echtzeit-Aktienkurs CRISPR Therapeutics AG
Bid:
Ask:
Nachrichten zur CRISPR Therapeutics AG Aktie
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $64.76, signifying a -1.97% move from its prior days close.…
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $66.06, moving 3.05% from the previous trading session.…
3 Monster Stocks in the Making to Buy Right Now
Key PointsCRISPR Therapeutics is still in its early growth stage.Summit Therapeutics has plenty of upside potential remaining.Viking Therapeutics is targeting…
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $52.73, denoting a -6.54% move from…
Heres Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $51.19, representing a -1.88% change from its previous close.…
2 Beaten-Down Stocks With Massive Upside Potential
There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues…
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be…
CRISPR Therapeutics AG (CRSP) Stock Moves 1.88%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.66, moving +1.88% from the previous trading session.…
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.…
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $46.78, marking a +2.7% move from the previous day.…
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
If youre looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening…
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Heres What You Need to Know
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $44.43, representing a +2.87% change from its previous close.…
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $42.94, representing a +2.02% change from its previous close.…
CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
…
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Even though broader equities have been highly volatile this year, its still a good idea to invest in stocks for…
CRISPR Therapeutics: Neue Kooperation – das steckt dahinter
Der weltweit führende CRISPR-Spezialist hat am Montag eine hochinteressante Zusammenarbeit bekanntgegeben. Gemeinsam mit Sirius Therapeutics sollen neuartige siRNA-Therapien zur Marktreife…
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past three years. The companys…
Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics?
One of the biggest opportunities in healthcare today centers around genome editing. According to analysts at Grand View Research, the…
2 Biotech Stocks That Are Screaming Buys in May
Its very tempting to pile into the stocks with the strongest positive momentum of the moment -- theyve proven themselves…
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -24.41% and 83.48%, respectively, for the quarter ended March 2025. Do…
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.25, moving +1.38% from the previous trading session.…
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the…
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day.…
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $38.54, denoting a -1.76% change from…
5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years
A "monster stock" might be one that frightens you by free-falling. Or it might alarm you with characteristics such as…
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.…
3 Magnificent Stocks That Could Double or More by 2030
When the stock market is as turbulent as it is these days, its easy to forget the times when things…
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire,…
CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $34.26, moving -1.81% from the previous trading session.…
CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)
…
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year,…
CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $32.65 in the latest trading session, marking a -0.03% move from the prior day.…
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Shares of biotechnology stocks such as Recursion Pharmaceuticals (NASDAQ: RXRX), Summit Therapeutics (NASDAQ: SMMT), and CRISPR Therapeutics AG (NASDAQ: CRSP)…
Crispr Therapeutics Aktie: Verliert ihren Kurs?
Der Austritt des operativen Geschäftsführers beim Gentherapie-Unternehmen beunruhigt Investoren und wirft Fragen zur Projektkontinuität im wettbewerbsintensiven Biotech-Sektor auf. Die Finanzmärkte...…
2 Beaten-Down Stocks to Buy on the Dip
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to…
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $41.22, indicating a +0.12% shift from the previous…
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day.…
Crispr Therapeutics Aktie: Positive Schlagzeilen
Die Führungsriege des Gentechnik-Unternehmens Crispr Therapeutics sorgte kürzlich mit umfangreichen Aktienverkäufen für Aufsehen an der Börse. Der Vorstandsvorsitzende trennte sich…
AKTIONÄR-Depotwert CRISPR Therapeutics: Plus 34 Prozent in einer Woche – geht die Aufholjagd weiter?
Der Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics scheint die Initialzündung gelungen zu sein. Nachdem die Aktie bereits in den vergangenen Tagen…
AKTIONÄR-Depotwert CRISPR Therapeutics: Plus 34 Prozent in einer Woche – geht die Aufholjagd weiter?
Der Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics scheint die Initialzündung gelungen zu sein. Nachdem die Aktie bereits in den vergangenen Tagen…
AKTIONÄR-Depotwert CRISPR Therapeutics: Aktie mit Kurssprung – spannendes Jahr voraus
Lange Zeit war es ruhig um die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics. In der vergangenen Woche hat sich das Papier…
AKTIONÄR-Depotwert CRISPR Therapeutics: Aktie mit Kurssprung – spannendes Jahr voraus
Lange Zeit war es ruhig um die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics. In der vergangenen Woche hat sich das Papier…
AKTIONÄR-Depotwert CRISPR Therapeutics: Aktie mit Kurssprung - spannendes Jahr voraus
Lange Zeit war es ruhig um die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics. In der vergangenen Woche hat sich das Papier…
CRISPR Therapeutics Aktie: Kursrally dank Analysten-Upgrade?
Kulmbach (www.aktiencheck.de) - CRISPR Therapeutics-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie der CRISPR Therapeutics AG…
AKTIONÄR-Depotwert CRISPR Therapeutics: "Neue Ära" – Kursziel 99 Dollar!
Mit einem vorbörslichen Kursplus von gut fünf Prozent kann die Aktie von CRISPR Therapeutics an die bisherige starke Wochenperformance anknüpfen.…
AKTIONÄR-Depotwert CRISPR Therapeutics: "Neue Ära" – Kursziel 99 Dollar!
Mit einem vorbörslichen Kursplus von gut fünf Prozent kann die Aktie von CRISPR Therapeutics an die bisherige starke Wochenperformance anknüpfen.…
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the…
CRISPR Therapeutics: Cathie Woods große Hoffnung
Seit mehr als sieben Jahren ist die US-Investorin Cathie Wood an dem Schweizer Pharmakonzern CRISPR Therapeutics beteiligt. Im vorangegangenen Quartal…
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 61.74% and 252.50%, respectively, for the quarter ended December 2024. Do…